From Wikipedia, the free encyclopedia
Drug for treatment of cancer
Aumolertinib
Trade names Ameile Other names Almonertinib; HS-10296
ATC code
Legal status
N -[5-[[4-(1-Cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide
CAS Number
PubChem
CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
Formula C 30 H 35 N 7 O 2
Molar mass 525.657 g·mol−1 3D model (
JSmol )
CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)C5CC5)OC
InChI=1S/C30H35N7O2/c1-6-29(38)32-24-17-25(28(39-5)18-27(24)36(4)16-15-35(2)3)34-30-31-14-13-23(33-30)22-19-37(20-11-12-20)26-10-8-7-9-21(22)26/h6-10,13-14,17-20H,1,11-12,15-16H2,2-5H3,(H,32,38)(H,31,33,34)
Key:DOEOECWDNSEFDN-UHFFFAOYSA-N
Aumolertinib (trade name Ameile ) is a pharmaceutical drug for the treatment of cancer.
[1] It is an
epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI).
[2]
In China, aumolertinib is approved for the treatment of patients with EGFR T790M mutation—positive
non-small-cell lung cancer (NSCLC) who have progressed on or after other EGFR TKI therapy.
[3]
[4]
References
^ Shirley M, Keam SJ (April 2022).
"Aumolertinib: A Review in Non-Small Cell Lung Cancer" . Drugs . 82 (5): 577–584.
doi :
10.1007/s40265-022-01695-2 .
PMID
35305259 .
^ Johnson ML, Miller VA, Patel S, Zhao Y, Cheng L, Ali SM, et al. "Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE)". Journal of Clinical Oncology . 41 (16).
doi :
10.1200/JCO.2023.41.16_suppl.TPS915 (inactive 17 April 2024). {{
cite journal }}
: CS1 maint: DOI inactive as of April 2024 (
link )
^
"Almonertinib Approved in China for EGFR T79M+ NSCLC" . onclive.com . 19 March 2020.
^ Lu S, Wang Q, Zhang G, Dong X, Yang CT, Song Y, et al. (March 2022).
"Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial" . Journal of Thoracic Oncology . 17 (3): 411–422.
doi :
10.1016/j.jtho.2021.10.024 .
PMID
34801749 .
CI
monoclonal antibodies ("-mab")
Tyrosine kinase inhibitors ("-nib")
Receptor tyrosine kinase
RET inhibitors:
Entrectinib (ALK, ROS1, NTRK),
Futibatinib (FGFR2),
Infigratinib ,
Larotrectinib (NTRK),
Pemigatinib (FGFR),
Pralsetinib ,
Repotrectinib (ROS1, TRK, ALK),
Selpercatinib (VEGFR, FGFR),
Vandetanib (VEGFR, EGFR).
Non-receptor
Other